drugset / Trial / NCT06603220
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
NaParallel-groupOpen-labelTreatment
Summary
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Timeline
- Start
- 2024-08-14
- Primary completion
- 2025-05-08
- Completion
- 2025-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EVO756 | Unknown | 50 mg | Oral |
| Subject | EVO756 | Unknown | 300 mg | Oral |